Next 10 |
2024-07-02 18:17:15 ET Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for W...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
2024-06-27 13:40:16 ET More on X4 Pharmaceuticals X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharma gains on new $125 financing...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2 nd Annual BioConnect Investor Co...
2024-05-09 07:30:10 ET More on X4 Pharmaceuticals X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 Pharmaceuticals GAAP EPS of -$0.26...
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024...
2024-05-07 13:33:09 ET X4 Pharmaceuticals Inc (XFOR) Q1 2024 Results Conference Call May 07, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - COO Mark Baldry - CMO Conference Call Par...
2024-05-07 06:05:57 ET More on X4 Pharmaceuticals X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside X4 Pharmaceuticals: PDUFA Excitement Ahead X4 gets FDA approval for Xolremdi for WHIM syndrome X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...